Therapeutic Efficacy and Fate of Bimodal Engineered Stem Cells in Malignant Brain Tumors
Open Access
- 6 February 2013
- journal article
- research article
- Published by Oxford University Press (OUP) in The International Journal of Cell Cloning
- Vol. 31 (8), 1706-1714
- https://doi.org/10.1002/stem.1355
Abstract
Therapeutically engineered stem cells (SC) are emerging as an effective tumor‐targeted approach for different cancer types. However, the assessment of the long‐term fate of therapeutic SC post‐tumor treatment is critical if such promising therapies are to be translated into clinical practice. In this study, we have developed an efficient SC‐based therapeutic strategy that simultaneously allows killing of tumor cells and assessment and eradication of SC after treatment of highly malignant glioblastoma multiforme (GBM). Mesenchymal stem cells (MSC) engineered to co‐express the prodrug converting enzyme, herpes simplex virus thymidine kinase (HSV‐TK) and a potent and secretable variant of tumor necrosis factor apoptosis‐inducing ligand (S‐TRAIL) induced caspase‐mediated GBM cell death and showed selective MSC sensitization to the prodrug ganciclovir (GCV). A significant decrease in tumor growth and a subsequent increase in survival were observed when mice bearing highly aggressive GBM were treated with MSC coexpressing S‐TRAIL and HSV‐TK. Furthermore, the systemic administration of GCV post‐tumor treatment selectively eliminated therapeutic MSC expressing HSV‐TK in vitro and in vivo, which was monitored in real time by positron emission‐computed tomography imaging using 18F‐FHBG, a substrate for HSV‐TK. These findings demonstrate the development and validation of a novel therapeutic strategy that has implications in translating SC‐based therapies in cancer patients. STEM Cells 2013;31:1706–1714This publication has 47 references indexed in Scilit:
- Mesenchymal stem cells engineered for cancer therapyAdvanced Drug Delivery Reviews, 2012
- Pharmacokinetic study of neural stem cell-based cell carrier for oncolytic virotherapy: targeted delivery of the therapeutic payload in an orthotopic brain tumor modelCancer Gene Therapy, 2012
- Encapsulated therapeutic stem cells implanted in the tumor resection cavity induce cell death in gliomasNature Neuroscience, 2011
- Neural Stem Cell-based Cell Carriers Enhance Therapeutic Efficacy of an Oncolytic Adenovirus in an Orthotopic Mouse Model of Human GlioblastomaMolecular Therapy, 2011
- An Inducible Caspase 9 Suicide Gene to Improve the Safety of Mesenchymal Stromal Cell TherapiesThe International Journal of Cell Cloning, 2010
- Adipose Tissue–derived Mesenchymal Stem Cells Expressing Prodrug-converting Enzyme Inhibit Human Prostate Tumor GrowthMolecular Therapy, 2010
- Long term non-invasive imaging of embryonic stem cells using reporter genesNature Protocols, 2009
- Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapyProceedings of the National Academy of Sciences of the United States of America, 2009
- Neural stem cells target intracranial glioma to deliver an oncolytic adenovirus in vivoGene Therapy, 2008
- Adipose Tissue–Derived Human Mesenchymal Stem Cells Mediated Prodrug Cancer Gene TherapyCancer Research, 2007